233 related articles for article (PubMed ID: 31478398)
1. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
El Helou G; Razonable RR
Expert Opin Drug Saf; 2019 Nov; 18(11):1017-1030. PubMed ID: 31478398
[No Abstract] [Full Text] [Related]
2. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.
Meesing A; Razonable RR
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):773-788. PubMed ID: 30009675
[TBL] [Abstract][Full Text] [Related]
3. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
4. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
Monday LM; Keri V; Chandrasekar PH
Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
[TBL] [Abstract][Full Text] [Related]
5. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Hakki M
Curr Hematol Malig Rep; 2020 Apr; 15(2):90-102. PubMed ID: 31981100
[TBL] [Abstract][Full Text] [Related]
6. New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Meesing A; Razonable RR
Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann N; Ljungman P; Styczynski J; Kröger N
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
[TBL] [Abstract][Full Text] [Related]
8. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
Yu MA; Park JM
Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
12. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
13. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
Deleenheer B; Spriet I; Maertens J
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
[TBL] [Abstract][Full Text] [Related]
15. Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.
Hamilton ST; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077661
[TBL] [Abstract][Full Text] [Related]
16. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
Haidar G; Boeckh M; Singh N
J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
[TBL] [Abstract][Full Text] [Related]
18. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
Hebart H; Kanz L; Jahn G; Einsele H
Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
[TBL] [Abstract][Full Text] [Related]
19. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
20. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]